在规范化诊治基础上改进和提高泌尿系统肿瘤综合治疗水平

泌尿系统肿瘤是严重威胁患者健康和生命的重要疾病,在临床上呈增多趋势,而对早期和晚期泌尿系统肿瘤的外科手术和非手术治疗已取得明显进展。例如,越来越多适合做根治手术的器官局限性前列腺癌被及时确诊,前列腺癌根治手术也不断优化、改进。根治性膀胱全切术的改良和完善,以及积极的围手术期干预,已使更多高龄、高手术风险的浸润性膀胱癌患者获得根治切除的机会。基于肾癌分子发病机制所研发的多种分子靶向药物,对晚期转移性肾癌患者的疗效已明显优于现有的细胞因子治疗,其从基础研究到临床创新的成功,不仅使肾癌以往缺乏有效非手术治疗的困境得到显著改善,也带动了更多有关肾癌发病机制的基础科研。因此,在泌尿系统肿瘤规范化诊疗的基础上,关注和应用这些进展,并开展相应的临床和基础研究,能为患者提供目前最好的综合治疗,达到更好改善患者生存和预后的目的。

The trends and progress in the comprehensive treatments of urological malignance

Urological malignance include a group of cancers of urinary system, the incidence of urological cancer shows increasing trend, while the increasing progress in both surgical and non-surgical treatments leads to better therapeutic effects to the patients of urological oncology. For example, more and more prostatic cancers are promptly diagnosed in the stage of organ-confined disease which is suitable for curable therapies, and the surgical technique of radical prostatectomy is well established and being optimized to guarantee the outcome of prostate cancer with the decrease of surgical complication. The improvements of radical cystectomy, along with the optimization of peri-operative intervention, are providing more curable opportunity to elderly and high operative risk patients of bladder cancer. The breakthrough of basic research on molecular pathogenesis of renal cell carcinoma, leads to the innovative clinical translation of molecular targeted therapy in the treatment of metastatic renal cancer. The great success of research and development on targeted therapy now are attracting more and more clinical and basic researches which possibly lead to promising novel treatments to urological malignance in the coming future. For the best clinical practice in urological oncology, it is necessary to pay tremendous attention on the advance of both clinical study and laboratory research, which would be the better way to more effectively improve the survival and prognosis of the patients of urological malignance with comprehensive treatments.